Top DoD in-vitro diagnostic substance manufacturing contractors
In the 12 months ending Oct 5, 2026, the Department of Defense obligated $50.8M in net prime contract dollars under NAICS 325413, up 5.0% from $48.4M in the preceding 12 months. 99 prime contractors received positive obligations, and 21 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Defense. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
DoD publishes contract data to USAspending with a 90-day delay, so the most recent months understate DoD activity.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top DoD contractors for NAICS 325413
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Roche Diagnostics Corporation | $7.6M | $7.6M | 14.9% | — |
| 2 | Hologic Sales and Service, LLC | $3.3M | $3.9M | 6.4% | — |
| 3 | Beckman Coulter, Inc | $3.1M | $1.7M | 6.0% | ▲ 4 |
| 4 | Abbott Laboratories Inc. | $2.8M | $2.5M | 5.4% | ▲ 1 |
| 5 | Siemens Healthcare Diagnostics Inc. | $2.5M | $2.8M | 4.8% | ▼ 2 |
| 6 | Biofire Defense LLC | $2.3M | $764K | 4.6% | ▲ 12 |
| 7 | Beckman Coulter Gesellschaft MIT Beschraenkter Haftung | $2.2M | $1.1M | 4.3% | ▲ 6 |
| 8 | Cepheid | $2.2M | $818K | 4.2% | ▲ 7 |
| 9 | Quidelortho Sales Company, LLC | $2.0M | $262K | 3.9% | ▲ 28 |
| 10 | Sysmex America, Inc | $1.9M | $1.7M | 3.6% | ▼ 4 |
| 11 | Diasorin Inc | $1.6M | $1.2M | 3.0% | — |
| 12 | Werfen USA LLC | $1.3M | $519K | 2.5% | ▲ 13 |
| 13 | Abbott Molecular Inc. | $1.2M | $141K | 2.4% | ▲ 39 |
| 14 | Fisher Scientific Company L.L.C. | $1.2M | $1.2M | 2.4% | ▼ 4 |
| 15 | Summit Shoji Inc. | $1.2M | $761K | 2.3% | ▲ 4 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Quidelortho Sales Company, LLC$262K → $2.0M (+$1.7M) · now #9
- Biofire Defense LLC$764K → $2.3M (+$1.6M) · now #6
- Beckman Coulter, Inc$1.7M → $3.1M (+$1.4M) · now #3
Largest declines
- Ortho-Clinical Diagnostics, Inc$2.5M → $525K (−$2.0M) · now #23
- Hologic, Inc.$1.5M → $74K (−$1.5M) · now #57
- Biofire Diagnostics LLC$988K → $0 (−$988K) · no latest-period obligations
New to this market
11 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Ventana Medical Systems, Inc | Mar 19, 2026 | $134K |
| Nichiei-Tokai Co., Ltd. | Jan 29, 2026 | $91K |
| Arkray Marketing, Inc. | Dec 4, 2025 | $64K |
| Biomerieux Japan Ltd. | Dec 9, 2025 | $64K |
| Defcol Global Trading WLL | Jun 26, 2026 | $62K |
| Roche Diagnostics S.P.A. | Dec 30, 2025 | $46K |
| Vitrolife Inc. | Dec 9, 2025 | $12K |
| Stemcell Technologies Inc | Jun 5, 2026 | $11K |
Where the money comes from
Funding sub-agencies within the Department of Defense, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Defense Health Agency | $46.3M | $35.2M | Up $11.2M (31.7%) |
| Defense Logistics Agency | $1.4M | $1.3M | Up $107K (8.4%) |
| Department of the Navy | $1.3M | $2.6M | Down $1.2M (47.5%) |
| Department of the Air Force | $913K | $977K | Down $64K (6.5%) |
| Department of the Army | $834K | $8.1M | Down $7.3M (89.7%) |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| W91YTZ25C0003 | Abbott Laboratories Inc. SLR FY25 CHEMISTRY ANALYZER/TESTING MACH | $1.2M | Oct 31, 2026 |
| W91YTZ24C0013 | Fisher Scientific Company L.L.C. FY25 SAF IMMUNO-ANALYZERS MICROBIOLOGY | $1.6M | Sep 30, 2027 |
| W81K0022P0111 | Hologic Sales and Service, LLC KIT, APTIMA COMBO 2 CT/GC 250 TEST | $1.5M | Sep 30, 2027 |
| W81K0025PA174 | Beckman Coulter, Inc COST PER-REPORTABLE RESULTS (CPRR) WITH AUTOMATED CORE LABORATORY | $1.5M | Sep 30, 2027 |
| W81K0022P0154 | Abbott Laboratories Inc. ANTI - HCV - IMMUNOASSAY TESTING | $1.4M | Sep 30, 2027 |
| W81K0025PA095 | Biofire Defense LLC MOLECULAR INFECTIOUS DISEASE POLYMERASE CHAIN REACTION (PCR) TESTING | $1.3M | Sep 30, 2027 |
| W81K0025CA008 | Abbott Molecular Inc. FOR MOLECULAR TRANSPLANT, RESPIRATORY, AND SEXUAL HEALTH TESTING DEPARTMENT OF PATHOLOGY AND AREA LABORATORY SERVICES | $1.2M | Sep 30, 2027 |
Common questions
Who are the top DoD contractors for NAICS 325413?
In the latest 12 months, Roche Diagnostics Corporation ($7.6M), Hologic Sales and Service, LLC ($3.3M), Beckman Coulter, Inc ($3.1M) received the most DoD obligations for in-vitro diagnostic substance manufacturing.
How concentrated is this market?
The eight largest primes held 50.8% of positive obligations, and Roche Diagnostics Corporation alone held 14.9%. 11 contractors won their first obligations in this market during the latest 12 months.
Are any large DoD NAICS 325413 contracts ending soon?
7 of the largest awards in this market reach their current end date in the next 18 months. The first is W91YTZ25C0003 (Abbott Laboratories Inc., $1.2M obligated), ending Oct 31, 2026. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 325413 across all agencies
VA · NAICS 325413
$105.5MHHS · NAICS 325413
$12.0MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.